Loading...
LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Phongpradist, Rungsinee Chittasupho, Chuda Okonogi, Siriporn Siahaan, Teruna J. Anuchapreeda, Songyot Ampasavate, Chadarat Berkland, Cory J.
Phongpradist, Rungsinee
Chittasupho, Chuda
Okonogi, Siriporn
Siahaan, Teruna J.
Anuchapreeda, Songyot
Ampasavate, Chadarat
Berkland, Cory J.
Citations
Altmetric:
Abstract
Leukemia therapeutics are aiming for improved efficacy by targeting molecular markers differentially expressed on cancerous cells. Lymphocyte function-associated antigen-1 (LFA-1) expression on various types of leukemia has been well studied. Here, the role and expression of LFA-1 on leukemic cells and the possibility of using this integrin as a target for drug delivery is reviewed. To support this rationale, experimental results were also included where cIBR, a cyclic peptide derived from a binding site of LFA-1, was conjugated to the surface of polymeric nanoparticles and used as a targeting ligand. These studies revealed a correlation of LFA-1 expression level on leukemic cell lines and binding and internalization of cIBR-NPs suggesting a differential binding and internalization of cIBR-NPs to leukemic cells overexpressing LFA-1. Nanoparticles conjugated with a cyclic peptide against an accessible molecular marker of disease hold promise as a selective drug delivery system for leukemia treatment.
Description
Date
2014-10-23
Journal Title
Journal ISSN
Volume Title
Publisher
Bentham Science Publishers
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
HL-60 cell line, LFA-1, Leukemia, Molt-3 cell line, Molt-4 cell line, Peptide, Nanoparticles, Targeting, U937 cell line
Citation
Phongpradist, Rungsinee, Chuda Chittasupho, Siriporn Okonogi, Teruna Siahaan, Songyot Anuchapreeda, Chadarat Ampasavate, and Cory Berkland. "LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery." Current Pharmaceutical Design 16.21 (2010): 2321-330.